Member Info for GLTader

Our SP today gives a market cap of £35m and we are in a net cash position. So, based on FY22/23 projections, which the company has reiterated, we are on 1.6x sales or under 3x GP.
Even conservatively at 5x sales and 9x GP, we should be at 15p. I say conservative because the industry multiples are much higher and we are back to pre-pandemic growth levels on core, and then you add US.
A sure sign will be new broker appointment, although not a pre-requisite.
Big upside potential with limited downside from here.

I think we all agree Yourgene is in the right space, with the right products and services, at the right time. Yourgene Genomic Services have invested in and pivoted towards whole genome sequencing. We are certified and also on govt roster. So, let's hope we get a slice of the action in this space.

Re your question Davand - I have mixed feelings re the Board. Having run and still run businesses, I do applaud the team for many achievements, including record year in FY21/22. But my biggest disappointment is in their investor relations and confidence building, as represented in our share price - even if not fully in their control. This is a key role of any Board, and in this respect, they have clearly underperformed.

I hope and remain hopeful they will pull a rabbit out of the hat. And soon!

Well, as our international sales return to pre-pandemic growth and with US market our core growth driver, the weak £ should give revenue a good lift of 15%! (last year average around 1.35 and now 1.10!)
It is fascinating, baffling and intriguing, whichever way you see it for the lack of news other than statutory periods - one cannot but wonder if it is client or deal embargo!
We are already so low - one big news and we can pop up easily. We all deserve it for being so patient!

I note that the Open Day agenda and presentation has been uploaded into website. Nothing much new but a good reminder of the progress the company is making. And for those intrigued re multiple addresses, it explains it in there.

Still hoping anyone who attended, who could be on this BB, to share the experience. A shame I couldn't make it.

Good also to note that EFK / ADL now has NIPT on their list of offering - previously only Covid! Ready for launch, clearly.

Let's look forward to a solid last quarter of the calendar year. Think we all deserve it! Back to December 2021 levels at 11p will be good start.

Waiting for feedback from anyone who attended the Open Day. Please, thank you.

The investment case for YGEN to me is clear:

- Share price / valuation today - clearly undervalued;
- We are in healthcare, and even more specifically in molecular diagnostics, which is less economically sensitive (grew
every year for last decade);
- Excluding Covid income, we are growing on our core again;
- We have multiple growth opportunities across geography, products and services; and
- We are ripe for consolidation / takeover given the cash rich positions of larger players post Covid.

Looking forward to the final quarter of the calendar year!

PS: Please stop all the nonsense chat. Really devalues this BB.

They sounded upbeat and had an attitude of "let us get on with doing what we are doing - you will see".
Certainly got the impression that pipeline is healthy, and perhaps it's me reading too much into it, they were more reserved in what they were saying - which leads me to believe they are bound by confidentiality.
APAC / lab installations was triple the rate in the this year versus last 12 months!
Chairman said they can't comment re take out rumours.
I think we could hear some exciting news in the next few weeks ahead of trading update.

A confident statement by YGEN / new chairman.
Even more convinced now we will be taken over imminently.

That is exactly what Lightbenct Detect is meant to deliver when comparing Streck v EBTA. Temperature differentials magnify the performance of the two......and it is with Lightbench Detect where samples are size-selected by gel electrophoresis to eliminate cfDNA fragments larger than 160bp, that eliminates the difference enabling similar performances - negating the need for Streck.

PS: Not Gentech, but Genmark.

I have titled the subject takeover imminent because I can't see any reason for the fall in SP over the last 6-9 months and at this share price, it must be imminent! As many will know, I have a substantial holding in YGEN - am of course feeling the pain many are feeling. This is nearing madness! With a market cap of £35m, we are at less than 2x sales and less than 3x GP - and we are in a category that is growing and will only continue to grow as healthcare become more personalised.

Each time I despair, I read again the 31 March 2022 glossy, the Capital Markets Day presentation and recent updates. I am convinced we have something here, and it is definitely nothing like a Vialogy. In fact, far from it.

Many criticise the management, understandably due to the share price performance, but I give them a lot of credit for proving their ability to adapt and deliver - delivering record revenues over the Covid period. To be able to pivot so quickly and commercialise, along with relevant certifications, is no mean feat. And now, to have a built a solid and broad foundation for growth.

BUT I am frustrated with the lack of news and the inability of the company to properly merchandise the progress they are making. There has been no notable RNS since EKF in January and Ambry in April. And yet, the number of labs using YGEN products have grown 30%+, three mega-labs are onboard, EKF and Ambry are due to launch next month, Ranger is validated by multiple academics and lab partners, etc etc. Each of these should be announced under RNS on a ongoing basis rather than hidden within investor presentations. Our customer base forms the basis of valuation since we make money from licensing but importantly, repeat consumables sales. Gentech before they were sold for $1.8b did this brilliantly.

Perhaps YGEN has signed confidentiality agreements that restrict what they can say amidst a corporate activity. Unless it is a whopper of a deal, YGEN should dictate certain terms too - we have the technology and products that can make the difference! We need to look after ourselves too.

Anyway, nothing suggests any change in company fundamentals. This has to be best bargain in the AIM right now. Good luck all.

Our sum of parts (as per my previous posting) is at least 200p!
We had (actual) bids to justify that when extrapolated.
This is just another validation.
KKR to buy Vantage - they might as well buy the lot! :-) Hence SP should / must be higher.

I think we are ok!

https://investors.vodafone.com/debt-investors/financing-strategy

Our share price APPALLING. The cynic (and optimist) in me have a suspicion that a takeover is being negotiated in the background, perhaps by those who are keeping a lid on YGEN commercial news. We can only based on investment decision (sell, buy, hold) on what we know and can validate. We know for certain:

3 large US clinical lab clients have been signed up:
- Labcorp (21.6.2021): Ranger tech for automated DNA size selection. This very much went under the radar until Labcorp actually presented on our behalf in Labroots. For those who don't know, Labcorp is the largest lab in US by revenue, in excess of $11b. They are publicly endorsing Ranger tech as a differentiation. I wouldn't be surprised with extension of their use for Ranger Revolution (ie Lightbench) and they do a lot of tests!!
- Ambry Genetics (9.06.2021): Full YGEN NIPT workflow including Ranger tech. Validation, customisation and certification for launch this month I think. Effective from 1 April 2022. We know this will be sizeable.
- Unknown (1.03.2021): Ranger tech for DNA enrichment and size selection. We know little about this one but again significant potential for cross / upselling. Given timing of others, I imagine it truly went live late last year even if licensing fee commenced on appointment.

We believe, although not confirmed by RNS, another megalab has signed up.
Lightbench Detect only launched in July 2022. This delivers significant savings via use of EBTA BCTs. All of these labs perform 6 figure blood tests annually, so there's your potential.

1 Japanese international molecular diagnostics signed up:
- Unknown (8.10.2020): Yourgene Flex across reproductive health. 5-year, $2.5m.

Circa 48 installed IONA Nx NIPT workflow labs globally. Not sure if this includes IONA - but that is quite a large base to work from. Each lab I am guessing circa £150,000 - £200,000 per annum.

100+ Products in the portfolio. Some leading ones including cystic fibrosis and DPYD.

ISO & relevant certified UK lab. Genomic Services proved its credence during Covid ramp up. Now re-focused on non-Covid and extended with Ambry oncology test suites.

So, when I review above, I definitely think we are significantly undervalued. Watch out for the takeover is what I think, and I am hoping it will be 200-300% premium to today's share price!

Relax!!
Company with 100+ products.
Unique technology in Ranger with SAM in the billions.
Proven track record in delivery with record year FY2022.

Add where you can. Enjoy the ride when we are taken over!
I bought into Micro Focus with same fundamental analysis and boom, acquisition at 532p.

YGEN........another takeover there very likely!

https://www.reuters.com/markets/deals/canadas-opentext-buy-software-firm-micro-focus-6-bln-deal-2022-08-25/?taid=6307efbb8903300001b09f28&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter

It is perhaps understandable, but a real shame, that people are making conjectures / allegations such as below.
If that's the premise you work off, then why stay on - I would never be invested in a company where I can't trust the management or feel they are being non-compliant!
I absolutely think Lyn & co are doing what they can - including buying 1m shares recently - and by end of this year, we may have totally different sentiments! If not already bought out!
And yes, I sat next to Dr Bill Chang at the CMD. I asked him point blank and he said no. You can believe that or not. Transferring shares to a company is probably a tax piece. You still have to declare ownership changes!

If you haven't, the full year glossy is well worth a read. The quality and content within certainly warrants a higher share price! If it's any consolation, and to know management will be pushing, all their share options are under water today!

https://www.yourgene-health.com/images/investor-relations/263747_Yourgene_Annual_Report_Web.pdf

Yes. That's my humble view.
Very bizarre we are where we are.

I invest based on fundamentals.
But do watch for signs and the recent trading activities certainly suggest something is brewing, whatever it is!
Guess we will know when we it comes.......